Dougherty & Co Upgrades Hologic (HOLX) to Buy; Believe the Inflection Point for Tomosynthesis Adoption is Just Around the Corner

Dougherty & Co upgraded Hologic (NASDAQ: HOLX) from Hold to Buy, price target raised from $20 to $26.

Dougherty analyst says, "We are upgrading Hologic and adjusting our PT to $26 as we believe pending data from the Oslo Study and recently introduced C-View software could be very meaningful for the adoption of Dimensions Tomosynthesis."

"For FY12, we’re raising our sales estimate to $1,931MM (previous $1,924MM) and raising our EPS estimate to $1.40 (previous $1.39). For FY12, we’re raising our sales estimate to $2,047MM (previous $2,014MM) and raising our EPS estimate to $1.52 (previous $1.47). Our adjustments presume higher sales of Dimensions Tomosynthesis."

For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.

Shares of Hologic closed at $20.73 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Solar Industries (SOIL:IN) PT Raised to INR23,500 at ICICI Securities
• LG Electronics India (LGEL:IN) PT Raised to INR1,815 at ICICI Securities